Programs & products

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory...

Treatment stopped in one arm of the study with remaining two arms continuing as per protocol Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company...

The trial rationale and protocol were presented at the “Targeted Anticancer Therapies” congress in Paris Phase I/II of IPH2201 as a single agent will begin in the next few months Innate Pharma SA (the...

First Phase II of IPH2201, a novel checkpoint inhibitor entering the immuno-oncology field Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing...

Lirilumab clinical development ongoing, including Phase II monotherapy trial in AML and three Phase I combination trials with nivolumab and elotuzumab Clinical program for lirilumab broadened with two...

Two posters presented by Bristol-Myers Squibb and Innate Pharma Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic...

IPH4102 is a first-in-class anti-KIR3DL2 monoclonal antibody in development for the treatment of cutaneous T-cell lymphoma (CTCL). Phase I trial is expected to start in 2015 IPH4102 shows potent...

This Phase I trial will test the safety and tolerability of lirilumab (BMS-986015) in combination with elotuzumab (BMS-901608) in patients with multiple myeloma This new Phase I initiated by Bristol...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today...

IPH4102 is a first-in-class anti-KIR3DL2 antibody Phase I is expected to start in 2015 Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing...